Jordan Gauthier
Fred Hutch/University of Washington Cancer Consortium
5
5
2
N/A
0
8
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+13 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Ajay Gopal
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Brenda Sandmaier
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Nitin Jain
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Leona Holmberg
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Ryotaro Nakamura
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Sikander Ailawadhi, M.D.
Mayo Clinic
Shared therapeutic areas:
Luhua (Michael) Wang
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Shaji Kumar
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy
huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
All 5 trials loaded